ROCHE HOLDING BJ Stock Euronext Paris
Equities
MLROH
CH0012032048
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- | - |
|
08:35am | Roche Obesity Pill Achieves Positive Results in Early-Stage Trial -- Update | DJ |
08:13am | Roche reports positive early results in obesity drug trial | RE |
Sales 2024 * | 60.47B 67.69B 0 92.58B | Sales 2025 * | 63.84B 71.45B 0 97.73B | Capitalization | 209B 234B 0 320B |
---|---|---|---|---|---|
Net income 2024 * | 13.43B 15.03B - 20.56B | Net income 2025 * | 14.85B 16.62B - 22.74B | EV / Sales 2024 * | 3.69 x |
Net Debt 2024 * | 14.28B 15.98B 0 21.86B | Net Debt 2025 * | 9.19B 10.29B 0 14.07B | EV / Sales 2025 * | 3.42 x |
P/E ratio 2024 * |
15.1
x | P/E ratio 2025 * |
13.8
x | Employees | - |
Yield 2024 * |
3.78% | Yield 2025 * |
3.88% | Free-Float | 88.91% |
Latest transcript on ROCHE HOLDING BJ
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
Director/Board Member | 59 | - | |
Director/Board Member | 66 | 95-12-31 |
1st Jan change | Capi. | |
---|---|---|
+61.53% | 848B | |
+33.75% | 627B | |
-3.66% | 363B | |
+15.06% | 318B | |
+9.18% | 299B | |
+15.11% | 225B | |
+15.67% | 179B | |
+2.47% | 167B | |
+2.40% | 125B |
- Stock Market
- Equities
- ROG Stock
- MLROH Stock